SPONSOR
Abramson Cancer Center at Penn Medicine
Total Trials
12
Recruiting
12
Phases
Phase 1, Phase 2, EARLY_Phase 1
Conditions studied: Fibrosis (Morphologic Abnormality)Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell LymphomaHigh-grade B-cell LymphomaTransformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaNeuroendocrine Tumor Grade 2Neuroendocrine TumorsColorectal Adenocarcinoma Metastatic in the LiverMesotheliomas Pleural
Abramson Cancer Center at Penn Medicine is a clinical research sponsor with 12 registered studies on ClinicalTrials.gov, of which 12 are actively recruiting participants. Research covers conditions including Fibrosis (Morphologic Abnormality), Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma.
The trial portfolio spans Phase 1, Phase 2, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Abramson Cancer Center at Penn Medicine
How many clinical trials has Abramson Cancer Center at Penn Medicine sponsored?
ClinicalMetric currently tracks 12 clinical trials sponsored by Abramson Cancer Center at Penn Medicine, of which 12 are actively recruiting participants. These trials cover conditions including Fibrosis (Morphologic Abnormality), Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Abramson Cancer Center at Penn Medicine research focus on?
Abramson Cancer Center at Penn Medicine clinical trials span Fibrosis (Morphologic Abnormality), Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Abramson Cancer Center at Penn Medicine clinical trial?
To participate in a Abramson Cancer Center at Penn Medicine trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Abramson Cancer Center at Penn Medicine trials with current recruitment status updated daily.
Clinical Trials by Abramson Cancer Center at Penn Medicine
NCT06413355 Phase 1
Recruiting
FAPI-74 PET/CT in Adults With Fibrosis
Fibrosis (Morphologic Abnormality)
NCT06458439 Phase 2
Recruiting
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Lymphoma, Non-Hodgkin
NCT04339036 Phase 2
Recruiting
CapTemY90 for Grade 2/3 NET Liver Metastases
Neuroendocrine Tumor Grade 2
NCT07082439 Phase 2
Recruiting
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Colorectal Adenocarcinoma Metastatic in the Liver
NCT03760575 Phase 1
Recruiting
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Mesotheliomas Pleural
NCT05427240
Recruiting
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
Cancer
NCT05612789
Recruiting
Improve Outcomes for Older Allogeneic Transplant Recipients
Allogeneic Transplantation
NCT03863457 Phase 1
Recruiting
[18F] F-GLN by PET/CT in Breast Cancer
Breast Cancer
NCT05659797 EARLY_Phase 1
Recruiting
FES BPET-DBT in Newly Diagnosed Breast Cancer
Breast Cancer
NCT06837480
Recruiting
Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
Head and Neck Cancer
NCT07278986 EARLY_Phase 1
Recruiting
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
Endometrial Cancer
NCT05932680 Phase 2
Recruiting
Limited-duration Teclistamab
Myeloma Multiple
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology